Archive

02 April 2017, Volume 33 Issue 4 Previous Issue    Next Issue

---

For Selected:

Download Citations EndNote Ris BibTeX

Toggle Thumbnails

Select

Diagnosis and management of patients with malignant vaginal melanoma ZHU Jian-Qing，YANG Li 2017, 33(4): 333-337.  DOI: 10.19538/j.fk2017040102 Abstract ( )   Malignant vaginal melanoma is a very rare malignant gynecological tumor associated with a poor prognosis due to high malignant degree，high metastatic rate and high recurrent rate.Surgical resection was the mainstay of primary therapy for early stage patients.Postoperative immunotherapy was appropriate option in high-risk patients.The multidisciplinary treatment was recommended for advanced stage patients.This review focuses on the literatures of case series，the latest researches and randomized clinical trials that led to change to the standards of care.

Select

Knowing carcinosarcoma of the female genital tract HUANG He，LIU Ji-hong 2017, 33(4): 338-342.  DOI: 10.19538/j.fk2017040103 Abstract ( )   Carcinosarcoma of the female genital tract is a rare but highly aggressive，easily recurrent malignancy with poor prognosis. Pathologically，carcinosarcoma is a biphasic neoplasm composed of a mixture of malignant epithelial and mesenchymal components. Studies have indicated that most carcinosarcomas are essentially high-grade  carcinomas with sarcomatous differentiation，which derive from a monoclonal neoplasm.A comprehensive approach to management is recommended with complete surgery，followed by multimodal therapy with combinations of external beam irradiation and/or systematic chemotherapy in patients with both early and advanced stage disease.

Select

Problems and countermeasures in the diagnosis and management of cervical neuroendocrine carcinoma XU Cong，DI Wen 2017, 33(4): 342-346.  DOI: 10.19538/j.fk2017040104 Abstract ( )   Neuroendocrine carcinoma of cervix is an aggressive，but rare，form of cervical cancer with an incidence of less than 3% of all cervical cancers.Nowadays，there are no prospective studies specific to this disease to guide the diagnosis and treatment.The Society of Gynecologic Oncology and Gynecologic Cancer Inter Group have issued consensus guidelines about the treatment for this disease based on the existing retrospective literature and expert opinion.Ongoing research is focused on further clarifying the best treatment regimen and defining molecular alterations of these tumors that can be exploited by novel treatment mechanisms.The objective of this manuscript is to review the literature，summarize current treatment recommendations，and propose possible research efforts for patients with neuroendocrine cervical cancer.

Select

Progress of diagnosis and therapy in uterine serous carcinoma WANG Chang，ZHU Yi 2017, 33(4): 346-350.  DOI: 10.19538/j.fk2017040105 Abstract ( )   The biological-clinical behaviors，treatment，and prognosis of uterine serous carcinoma are significantly different from typeⅠ endometrial carcinoma.The behavior of uterine serous carcinoma is highly malignant and is likely to result in distant metastases.This article elaborates its epidemiology，clinical feature，diagnosis criteria and treatment progress，hoping to help the clinical diagnosis and treatment.

Select

Diagnosis and treatment of epithelioid trophoblastic tumor DU Jiang-yue，LYU Wei-guo 2017, 33(4): 350-353.  DOI: 10.19538/j.fk2017040106 Abstract ( )   Epithelioid trophoblastic tumor（ETT）is a rare tumor which originates from the chorionic intermediate trophoblast.It occurs mostly in women of childbearing age，especially after full-term pregnancy.The clinical manifestation of ETT is similar to that of placental site trophoblastic tumor（PSTT）.About 70% of ETT patients have the complaint of vaginal bleeding，and moderate up-regulation of serum human chorionic gonadotropin （hCG） levels is widely found.Surgery is the preferred option for the treatment of ETT，and the effect of chemotherapy remains controversial.Patients without metastasis have a favourable prognosis，but metastasis comes with a very poor prognosis.

Select

Diagnosis and treatment of placental site trophoblastic tumor ZHAO Jun，XIANG Yang 2017, 33(4): 353-357.  DOI: 10.19538/j.fk2017040107 Abstract ( )   Placental site trophoblastic tumor is a rare form of gestational trophoblastic disease.The most common clinical manifestations are amenorrhea and abnormal vaginal bleeding. The diagnosis must be based on pathological evidence.Immunohistochemistry plays an important role in the diagnosis and differential diagnosis of PSTT.PSTT is less chemosensitive than other forms of gestational trophoblastic neoplasm，thus operation is the primary treatment in most cases.Multiple agent chemotherapy combined with operation are recommended in patients with poor prognostic factors.Fertility-preserving treatment can be considered in highly-selected cases.

Select

How to improve the curative effect on ovarian carcinosarcoma ZHU Jun，WU Xiao-hua 2017, 33(4): 357-360.  DOI: 10.19538/j.fk2017040108 Abstract ( )   Ovarian carcinosarcoma（OCS）is highly aggressive and rare tumors differing from other malignant gynecological tumors，which are composed of both epithelial and mesenchymal elements.Clinically OCS is more aggressive and less sensitivive to chemotherapy and radiotherapy with worse prognosis.The treatment for carcinosarcoma is mainly composed of surgery and adjuvant therapy.With the advanced research on the gene expression，targeted therapies present a promising potential for the improvement of the prognosis.

Select

Current status and prospect of the study on ovarian cancer associated with endometriosis WANG Shu，LANG Jing-he 2017, 33(4): 360-364.  DOI: 10.19538/j.fk2017040109 Abstract ( )   Endometriosis is one of the most common benign gynecologic diseases.Malignant changes of endometriosis（EM）are considered to have close relationship with ovarian clear cell carcinoma and endometrioid adenocarcinoma，and EM is regarded as the precursor lesion of OCCC.Previous clinical studies showed endometriosis-associated ovarian cancer（EAOC）patients have some special clinical and pathological features，and prognosis is good.And the basic research found that certain abnormal expression of genes was related to EAOC.Future research might focus on exploring new molecular target of EAOC，so as to guide the clinical screening of high risk population，predict disease progression，and help to build the precise classification system of ovarian cancer and the strategy of stratified management.

Select

Adjuvant therapy for patients with malignant ovarian sex cord-stromal tumor CAO Dong-yan，YANG Ni 2017, 33(4): 364-367.  DOI: 10.19538/j.fk2017040110 Abstract ( )   Ovarian sex cord-stromal tumors are a group of tumors with heterogeneity，most of which are benign.Malignant ovarian sex cord- stromal tumors are rare with lower risks of recurrent and metastasis.Surgical resection is the major approach of treatments.Adjuvant chemotherapy was offered for patients with risk factors of recurrence，though lack of supporting data from prospective，randomized clinical trials.

Select

Diagnosis and treatment of female genital system lymphoma ZHOU Ming-yi，WANG Dan-bo 2017, 33(4): 367-371.  DOI: 10.19538/j.fk2017040111 Abstract ( )   Primary female genital system lymphoma（PFGSL） is one kind of extranodal lymphoma.PFGSLs include ovarian lymphomas，cervical lymphomas and vulvar lymphomas.Most of PFGSLs are type B non- Hodgkin’s lymphoma.The diagnosis is based on pathology and immunohistochemistry.The treatment strategies include CHOP-based chemotherapy，targeted therapy，radiotherapy and surgery.The purpose of surgery is to clarify the pathology.Rituximab has been demonstrated to improve the prognosis of lymphoma.The prognosis of PFGSL is good.

Select

Prevention and treatment of ovarian cancer after operation for breast cancer LI Qian，WANG Chun-yan 2017, 33(4): 371-376.  DOI: 10.19538/j.fk2017040112 Abstract ( )   Breast cancer remains the most common cancer in the female.If patients had unmarried history，family history，the history of three-negative breast cancer or oral selective estrogen antagonists and BRCA1/BRCA2 mutations，we should be specially alerted that the patients after operation for breast cancer might have the possibility of happening ovarian cancer.There are several methods including gene detection，clinical screening and risk-reducing salpingo-oophorectomy（RRSO），which can prevent incidence of ovarian cancer after operation for breast cancer.The patients should receive treatment as soon as possible.The proportion of patients with ≥5 years of interval incidence time is the highest，which means the long-term follow-up is necessary.